ERGOMED Group’s fast-growing services business includes a full range of high-quality clinical research and trial management services under the Ergomed Clinical Research brand, an industry-leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and full range of GxP Audits from early development through to post-marketing surveillance under the ADAMAS Consulting brand. The ERGOMED Group employs over 1,800 people and operates out of 27 offices around the world, providing its services to researchers and patients in around 100 countries globally.

Ergomed Clinical Research is a global leader in delivering specialized services in oncology, rare disease, and complex trials to the pharmaceutical and biotech sectors. Our comprehensive support covers the entire clinical trial process, from early phase to post-approval, offering full-service, industry-leading clinical trial management solutions as a trusted partner. Our integrated service model helps life sciences companies meet regulatory obligations, maximize drug development success, and enhance the patient experience.

PrimeVigilance is a global leader in pharmacovigilance and specialised multi-lingual medical information services. Since 2008, the PrimeVigilance business has supported pharmaceutical, biotechnology and genetics companies in managing the global safety of their products, all the way from clinical trial to post-marketing.  Our pharmacovigilance services include case processing, signal and risk management, pharmacoepidemiology, audits, training, advisory literature services, medical information and QPPV.

ADAMAS Consulting has conducted thousands of GxP audits in over 100 countries for over 750 international clients. We are committed to providing all our clients with the highest level of service in every country. With offices in three continents, our global capabilities allow ADAMAS to provide coverage for a wide range of healthcare clients, operating internationally.